Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × empagliflozin × 1 year × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Carboplatin 193 pembrolizumab 188 Cisplatin 179 Paclitaxel 160 Gemcitabine 130 Docetaxel 109 Capecitabine 101 Cyclophosphamide 93 Pemetrexed 89 Dexamethasone 89 Specimen Handling 85 Doxorubicin 85 Magnetic Resonance Spectroscopy 84 Oxaliplatin 83 Radiotherapy 80 Fluorouracil 74 Bevacizumab 71 Nivolumab 69 Rituximab 65 Leucovorin 64 Vincristine 61 durvalumab 59 Lenalidomide 58 atezolizumab 54 Etoposide 54 Radiation 53 Prednisone 53 Irinotecan 52 Trastuzumab 50 Drug Therapy 48

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡